TST

Across TCGA pan-cancer cohorts, TST mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TST data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TST mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TST expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where TST mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.968	0.378	.010	26	view →
CCRCC	OS	Median	III,IV	0.964	0.807	.042	7	view →
UCEC	DFS	Quartile	III,IV	0.343	1.000	.027	4	view →
LUAD	DFS	Quartile	All	0.854	0.361	.004	3	view →
HNSC	OS	Median	All	0.616	0.773	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TST–PDAC (OS)

Open the PDAC breakdown →